Douglas Jolly, Ph.D., is a co-founder of Tocagen and has served as our executive vice president, research and pharmaceutical development since December 2007. He is an internationally recognized expert in the field of gene therapy and its pharmaceutical application. Over the last 25 years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., where he was also a co-founder, Chiron Corporation, Oxford BioMedica plc, where he ran the U.S. subsidiary, BioMedica Inc., and Advantagene, Inc., where he most recently served as president. He has published more than one hundred scientific articles and is an inventor on more than forty-five issued patents. Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute; Harvard Medical School; Scripps Clinic; University of California, San Diego; and The French National Institute for Health and Medical Research, INSERM, in Paris. Dr. Jolly holds a doctorate in biochemistry from the University of Glasgow. Dr. Jolly is a board member, chairman of the Industrial Liaison Committee, and also currently serves as a member of the Translational Medicine Committee of the American Society of Gene & Cell Therapy.